Carvolix Raises €10M from Edwards Lifesciences and Truffle Capital at €3.36
On Wednesday, medical technology company Carvolix announced the completion of a €10M funding round from its strategic shareholders, bringing its total cash resources to €20M. This funding is intended to support the commercial rollout of its Tavipilot robotic platform in the United States and to advance several regulatory and clinical milestones over the coming quarters.
Funding Reserved for Existing Strategic Investors
Carvolix issued 2,976,190 new ordinary shares at a price of €3.36, equivalent to the weighted average price over the last 30 days. The placement, reserved for specific categories of investors, targets strategic funds already invested in the company, venture capital funds, business angels, and potential commercial partners. Edwards Lifesciences and funds managed by Truffle Capital — both existing shareholders — each acquired €5M (1,488,095 shares). Following the settlement-delivery scheduled for around June 26, 2026, the new shares will represent 5.02% of the company's capital.
Strengthening Cash Reserves Until End of September 2026
The €10M raised will serve two purposes: funding the development of several products (30% for Tavipilot, 23% for Kalios, 21% for Artus, 19% for Artedrone, 7% for Mitrapilot) and repaying €2.5M of bridge financing provided by Truffle Capital. The company estimates that its existing cash resources, supplemented by this payment, will enable it to fund its operations until the end of September 2026. Carvolix plans to extend its financing capacity beyond 12 months by contracting a venture debt facility of approximately €25M, currently under negotiation with several European funds.
Expected Catalysts Until End of 2026
Carvolix identifies several key milestones to be achieved in the coming months. In the third quarter of 2026: submission of the Tavipilot Robot to the FDA, communication of clinical results, and publication of a hemodynamic study for Mitrapilot. In the fourth quarter of 2026: CE marking for the Tavipilot software, FDA 510(k) approval for the Tavipilot robot, and resumption of the European clinical trial for Kalios.
